GlassScriptPhysician profile
Michael S Hogue
NPI 1619943503
$1,970.79
in general payments reported to CMS, 2019-2025
33 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $157 · 2021: $20.75 · 2022: $46.75 · 2023: $69.10 · 2024: $115 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.24 | 2019-2024 | |
| Amgen INC. | $267.57 | 2019-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.60 | 2019-2025 | Ofev, Jardiance |
| Novo Nordisk INC | $190.86 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Celgene Corporation | $83.47 | 2019 | |
| Lilly USA, LLC | $71.61 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $68.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.93 | 2019-2023 | |
| Valeritas, INC. | $46.21 | 2019 | |
| Janssen Biotech, INC. | $41.94 | 2019 | |
| Corcept Therapeutics | $39.36 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $37.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.67 | 2019 | |
| Radius Health, INC. | $29.55 | 2025 | |
| Janssen Pharmaceuticals, INC | $27.99 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.21 | 2025 | Capvaxive |
| Abbott Laboratories | $25.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.40 | 2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $22.64 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.60 | 2024 | Voquezna |
| Beta Bionics, INC. | $21.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $20.75 | 2021 | |
| Medtronic, INC. | $19.24 | 2025 | Intellis Adaptivestim |
| Mallinckrodt Enterprises LLC | $18.33 | 2019 | |
| Madrigal Pharmaceuticals | $17.43 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $15.97 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $14.78 | 2023 | Inspire |
| Cequr Corporation | $14.50 | 2024 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $13.94 | 2020 | |
| Ucb, INC. | $12.63 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hogue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.